|
|
Volumn 19, Issue 6, 2002, Pages 413-425
|
|
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANDROSTANOLONE;
AZASTEROID;
DUTASTERIDE;
FINASTERIDE;
STEROID 5ALPHA REDUCTASE;
AGED;
AGING;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
DOSE RESPONSE;
DRUG ADMINISTRATION;
DRUG EFFECT;
ENZYMOLOGY;
HUMAN;
MALE;
METABOLISM;
MIDDLE AGED;
MULTICENTER STUDY;
ORAL DRUG ADMINISTRATION;
PATHOLOGY;
PHASE 3 CLINICAL TRIAL;
PHYSIOLOGY;
PROBABILITY;
PROGNOSIS;
PROSTATE HYPERTROPHY;
REVIEW;
TREATMENT OUTCOME;
ADMINISTRATION, ORAL;
AGED;
AGING;
AZASTEROIDS;
CLINICAL TRIALS, PHASE III;
CONTROLLED CLINICAL TRIALS;
DIHYDROTESTOSTERONE;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FINASTERIDE;
HUMANS;
MALE;
MIDDLE AGED;
MULTICENTER STUDIES;
PROBABILITY;
PROGNOSIS;
PROSTATIC HYPERPLASIA;
TESTOSTERONE 5-ALPHA-REDUCTASE;
TREATMENT OUTCOME;
|
|
EID: 0036545464
PISSN: 07244983
EISSN: None
Source Type: Journal
DOI: 10.1007/s00345-002-0248-5 Document Type: Review |
|
Times cited : (122)
|
|
References (0)
|
